JP2006525980A - セロトニン５−ｈｔ１７レセプターアンタゴニスト活性及びムスカリンｍ４レセプターアゴニスト活性を有する化合物及び精神病の治療でのそれらの使用 - Google Patents

セロトニン５−ｈｔ１７レセプターアンタゴニスト活性及びムスカリンｍ４レセプターアゴニスト活性を有する化合物及び精神病の治療でのそれらの使用 Download PDF

Info

Publication number
JP2006525980A
JP2006525980A JP2006506051A JP2006506051A JP2006525980A JP 2006525980 A JP2006525980 A JP 2006525980A JP 2006506051 A JP2006506051 A JP 2006506051A JP 2006506051 A JP2006506051 A JP 2006506051A JP 2006525980 A JP2006525980 A JP 2006525980A
Authority
JP
Japan
Prior art keywords
group
receptor
arh
muscarinic
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006506051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525980A5 (https=
Inventor
エヴァンゲロウ リゾス、ディミトリオス
マッカーチャー、クレア
マーフィー、ジョン
康之 椎木
サックリング、コリン
浩 安松
ツォウ、シェン−ゼ
プラット、ジュディス
モリス、ブライアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0307366A external-priority patent/GB0307366D0/en
Priority claimed from GB0307370A external-priority patent/GB0307370D0/en
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of JP2006525980A publication Critical patent/JP2006525980A/ja
Publication of JP2006525980A5 publication Critical patent/JP2006525980A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2006506051A 2003-03-29 2004-03-29 セロトニン５−ｈｔ１７レセプターアンタゴニスト活性及びムスカリンｍ４レセプターアゴニスト活性を有する化合物及び精神病の治療でのそれらの使用 Withdrawn JP2006525980A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0307366A GB0307366D0 (en) 2003-03-29 2003-03-29 Compounds
GB0307370A GB0307370D0 (en) 2003-03-29 2003-03-29 Compounds I
PCT/GB2004/001367 WO2004087124A1 (en) 2003-03-29 2004-03-29 Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders

Publications (2)

Publication Number Publication Date
JP2006525980A true JP2006525980A (ja) 2006-11-16
JP2006525980A5 JP2006525980A5 (https=) 2006-12-28

Family

ID=33133138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006506051A Withdrawn JP2006525980A (ja) 2003-03-29 2004-03-29 セロトニン５−ｈｔ１７レセプターアンタゴニスト活性及びムスカリンｍ４レセプターアゴニスト活性を有する化合物及び精神病の治療でのそれらの使用

Country Status (4)

Country Link
US (1) US20060199978A1 (https=)
EP (1) EP1608354A1 (https=)
JP (1) JP2006525980A (https=)
WO (1) WO2004087124A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130029846A1 (en) 2010-03-29 2013-01-31 Basf Se Fungicidal Iminoderivatives
NO346598B1 (en) 2020-12-23 2022-10-24 Klingelberg Products As Method for the preparation of amidines and amide manufactured by the method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL27999A (en) * 1966-05-25 1971-08-25 Egyt Gyogyszervegyeszeti Gyar Naphthyl-and tetrahydronaphthyl-formamidines
DE2849558A1 (de) * 1978-11-15 1980-05-29 Bayer Ag Substituierte phenyliminomethyl- harnstoffe, verfahren zu ihrer herstellung und ihre verwendung als pflanzenbakterizide
SE9500998D0 (sv) * 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics
JP2001510797A (ja) * 1997-07-22 2001-08-07 イーライ・リリー・アンド・カンパニー 医薬化合物

Also Published As

Publication number Publication date
EP1608354A1 (en) 2005-12-28
US20060199978A1 (en) 2006-09-07
WO2004087124A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
DE69431462T2 (de) Glycoprotein IIb/IIIa Antagonisten
AU2014267974B2 (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
TWI391385B (zh) An amine-based indane derivative or a salt thereof
CZ2004501A3 (cs) Chinuklidinové deriváty, způsoby jejich přípravy a jejich použití jako M2 a/nebo M3 inhibitoru muskarinového receptoru
TW201418255A (zh) ４－甲基－２，３，５，９，９ｂ－五氮雜－環戊［ａ］萘
JP2013501013A (ja) 代謝調節型グルタミン酸受容体モジュレーター
JPH07119213B2 (ja) ムスカリンリセプターアンタゴニスト
CN107922340B (zh) 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
JP2024515614A (ja) 脳障害を治療するための四環式化合物
JP2010517958A (ja) ＰＤＥ５インヒビターとして有用な６−ベンジル−２，３，４，７−テトラヒドロ−インドロ［２，３−ｃ］キノリン化合物
JP4748320B2 (ja) 環状アミン誘導体又はその塩
EP2137180B1 (en) Dibenzo [b,f][1,4] oxazapine compounds
JPH037257A (ja) ピリジン誘導体及びそれを有効成分とする向精神剤
JP5747910B2 (ja) ベンゾアゼピン化合物
WO2022237782A1 (zh) 酰胺衍生物及其应用
JPS60218377A (ja) ４−フエニルフタラジン誘導体及びそれを有効成分とする循環改善剤
JP3471778B2 (ja) 三環性縮合複素環化合物、その製造方法および用途
JP2006525980A (ja) セロトニン５−ｈｔ１７レセプターアンタゴニスト活性及びムスカリンｍ４レセプターアゴニスト活性を有する化合物及び精神病の治療でのそれらの使用
JPH04178356A (ja) 光学活性なベンジルアルコール誘導体及びその用途
DE602005006018T2 (de) Arylpiperazinderivate und deren verwendung als für den dopamin-d3-rezeptor selektive liganden
KR20250132455A (ko) 상피 및/또는 내피 장벽 기능을 강화하기 위한 치료제
WO2024027845A1 (zh) 双四氢呋喃类化合物作为α-突触核蛋白聚集体形成抑制剂的用途、包含其的药物组合物
WO2019163865A1 (ja) 含窒素複素環を有するジベンゾアゼピン誘導体
KR20250019650A (ko) 화합물
WO2018139471A1 (ja) ジベンゾジアゼピン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061030

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20071102

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090427